参考实验室对氧氟沙星基线耐药的耐多药结核病患者对莫西沙星和左氧氟沙星的额外耐药性

V. Ahmad, Z. Sidiq, H. Vashishtha, M. Hanif, Divy Shrivastsava, K. Dwivedi, S. Saini, K. Chopra, V. K. Badireddy, J. Bhalla
{"title":"参考实验室对氧氟沙星基线耐药的耐多药结核病患者对莫西沙星和左氧氟沙星的额外耐药性","authors":"V. Ahmad, Z. Sidiq, H. Vashishtha, M. Hanif, Divy Shrivastsava, K. Dwivedi, S. Saini, K. Chopra, V. K. Badireddy, J. Bhalla","doi":"10.4172/2155-952X.1000239","DOIUrl":null,"url":null,"abstract":"Fluoroquinolones are among the most promising antibiotic drugs for Tuberculosis treatment. Although high levels of fluoroquinolone resistance have been detected among many common bacterial pathogens, little is known about the fluoroquinolone resistance of M. tuberculosis especially at the baseline. The present study was thus aimed at determining the profile of resistance against two newer generation fluoroquinolones-Moxifloxacin and Levofloxacin in MDR-TB isolates with baseline resistance to ofloxacin. A total number of 65 isolates (4 XDR and 61 pre-XDR) were subjected to susceptible testing against levofloxacin and two (higher and lower) concentrations of moxifloxacin. 72.3% in addition to being resistant to ofloxacin were also resistant to levofloxacin and lower concentration of moxifloxacin. The increasing use of FQs for the treatment of other bacterial infections has led to increasing resistance to these antimicrobials. Newer generation FQs are promising drugs in the treatment of drugresistant Tuberculosis but care should be taken regarding the rationale use of these drugs for the treatment of other diseases especially when other drugs are available.","PeriodicalId":15156,"journal":{"name":"Journal of biotechnology & biomaterials","volume":"20 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2016-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Additional Resistance to Moxifloxacin and Levofloxacin among MDR-TB Patients with Base Line Resistance to Ofloxacin at a Reference Laboratory\",\"authors\":\"V. Ahmad, Z. Sidiq, H. Vashishtha, M. Hanif, Divy Shrivastsava, K. Dwivedi, S. Saini, K. Chopra, V. K. Badireddy, J. Bhalla\",\"doi\":\"10.4172/2155-952X.1000239\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Fluoroquinolones are among the most promising antibiotic drugs for Tuberculosis treatment. Although high levels of fluoroquinolone resistance have been detected among many common bacterial pathogens, little is known about the fluoroquinolone resistance of M. tuberculosis especially at the baseline. The present study was thus aimed at determining the profile of resistance against two newer generation fluoroquinolones-Moxifloxacin and Levofloxacin in MDR-TB isolates with baseline resistance to ofloxacin. A total number of 65 isolates (4 XDR and 61 pre-XDR) were subjected to susceptible testing against levofloxacin and two (higher and lower) concentrations of moxifloxacin. 72.3% in addition to being resistant to ofloxacin were also resistant to levofloxacin and lower concentration of moxifloxacin. The increasing use of FQs for the treatment of other bacterial infections has led to increasing resistance to these antimicrobials. Newer generation FQs are promising drugs in the treatment of drugresistant Tuberculosis but care should be taken regarding the rationale use of these drugs for the treatment of other diseases especially when other drugs are available.\",\"PeriodicalId\":15156,\"journal\":{\"name\":\"Journal of biotechnology & biomaterials\",\"volume\":\"20 1\",\"pages\":\"1-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-08-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of biotechnology & biomaterials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-952X.1000239\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biotechnology & biomaterials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-952X.1000239","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

摘要

氟喹诺酮类药物是治疗结核病最有前途的抗生素药物之一。虽然在许多常见的细菌病原体中检测到高水平的氟喹诺酮耐药性,但对结核分枝杆菌的氟喹诺酮耐药性知之甚少,特别是在基线。因此,本研究旨在确定对氧氟沙星基线耐药的耐多药结核分离株对两种新一代氟喹诺酮类药物——莫西沙星和左氧氟沙星的耐药情况。共对65株菌株(4株XDR和61株XDR前菌株)进行左氧氟沙星和两种(高、低)浓度莫西沙星的敏感试验。72.3%的患者除对氧氟沙星耐药外,还对左氧氟沙星和低浓度莫西沙星耐药。FQs越来越多地用于治疗其他细菌感染,导致对这些抗菌素的耐药性增加。新一代FQs是治疗耐药结核病的有希望的药物,但应注意使用这些药物治疗其他疾病的理由,特别是在有其他药物可用的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Additional Resistance to Moxifloxacin and Levofloxacin among MDR-TB Patients with Base Line Resistance to Ofloxacin at a Reference Laboratory
Fluoroquinolones are among the most promising antibiotic drugs for Tuberculosis treatment. Although high levels of fluoroquinolone resistance have been detected among many common bacterial pathogens, little is known about the fluoroquinolone resistance of M. tuberculosis especially at the baseline. The present study was thus aimed at determining the profile of resistance against two newer generation fluoroquinolones-Moxifloxacin and Levofloxacin in MDR-TB isolates with baseline resistance to ofloxacin. A total number of 65 isolates (4 XDR and 61 pre-XDR) were subjected to susceptible testing against levofloxacin and two (higher and lower) concentrations of moxifloxacin. 72.3% in addition to being resistant to ofloxacin were also resistant to levofloxacin and lower concentration of moxifloxacin. The increasing use of FQs for the treatment of other bacterial infections has led to increasing resistance to these antimicrobials. Newer generation FQs are promising drugs in the treatment of drugresistant Tuberculosis but care should be taken regarding the rationale use of these drugs for the treatment of other diseases especially when other drugs are available.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Biodegradable microparticles with hierarchical topographical features influence mesenchymal stem cell behaviour Antimicrobial nano-fiber structures development to rejuvenate injured dura mater in brain surgery Cellulase production with Penicillium verruculosum strain in lab and pilot scale Human metaplastic breast carcinoma and decorin Epitranscriptomic blood biomarkers to manage psychiatric disorders
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1